Hypertension

A recent analysis found patients with benign adrenal tumors and MACS were at an increased risk of cardiometabolic diseases.

In comparison to men, women with ASCVD were more likely to report being clinically depressed, have cost-related medication nonadherence, and have not seen a physician due to cost.

Each month, our editorial staff compiles a month in review highlighting the most popular content from the past month. December's month in review features new guidelines, FDA news, and more.

Released on Dec. 15, the latest scientific statement from the American Heart Association provides a comprehensive overview of the available evidence on topics related to diagnosis, management, and pharmacotherapy for hypertension during pregnancy.

The Practical Cardiology editorial staff has compiled a list of 6 noteworthy posters related to cardiology from the Metabolic Institute of America's 19th annual World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease.

A report published in Circulation details per month increases in both systolic and diastolic blood pressure observed during the pandemic as compared with prepandemic periods.

Obesity is a risk factor for both obstructed sleep apnea and IHH.

Data show the absolute risk difference for the development of PPHN after exposure to antidepressants in late pregnancy was 1.3 per 1000 infants.

Data show the multivariable-adjusted HR for increase in seafood consumption of 1 oz per day and all-cause mortality was 0.84 and for CVD-related mortality was 0.89.

Study data show for each $1,000 decrease in median household income, the number of TAVR procedures performed per 100,000 Medicare beneficiaries was 0.2% lower.

The latest data from the digital care transformation program provides insight into effects of digital monitoring programs on helping patients achieve blood pressure and cholesterol goals.

More than 90% of patients in hypertension and lipid management accomplished their predetermined goals after completing the remote program.

Epinephrine before defibrillation was associated with lower odds of survival to discharge, favorable neurological survival, and survival after acute resuscitation

The treatment cannot be granted full approval due to ongoing litigation.

Data from the CLICK trial presented at ASN Kidney Week 2021 suggests the use of chlorthalidone could reduce blood pressure by 11 mmHg among patients with stage 4 chronic kidney disease and poorly controlled hypertension.

Data show reduction in systolic BP was considered greater than safety concerns related to drugs and interventional treatment, and preference for no intervention over intervention.

Results of the 6-month follow-up from RADIANCE-HTN TRIO suggest the addition of antihypertensive medications following renal denervation could contribute to further blood pressure lowering in patients with treatment-resistant hypertension.

The adjusted change in 24-hour systolic blood pressure was -11.0 mm Hg in the chlorthalidone group and -0.5 mm Hg in the placebo group.

In patients with advanced heart failure, the median NT-proBNP AUC for valsartan was 1.19 compared to an AUC of 1.08 for sacubitril/valsartan.

The American College of Cardiology and American Heart Association guideline provides key highlights into the evaluation and diagnosis of adult patients with chest pain.

Data show nonfatal MI did not meet the threshold for surrogacy for all-cause mortality or CV mortality.

Gregory Weiss, MD, provides perspective on a recent scientific statement from the AHA outlining the role of health systems in promoting optimal adherence to hypertension therapies and helping patients achieve treatment goals.

In 1774 estimated discharges where a hospital region in the US had been indicated, 35.9% were diagnosed in the West and 32.3% in the South.

Women who delivered preterm had a greater than 1.6-fold risk of hypertension and women who delivered extremely preterm had a 2.2-fold risk within the next 10 years.

The letter pointed to a single deficiency related to an open inspection issue at a third-party facility.